TRAIL and Bortezomib: killing cancer with two stones.
Cancer genomics and proteomics have undergone considerable broadening in the past decades and increasingly it is being realized that solid/liquid phase microarrays and high-throughput resequencing have provided platforms to improve our existing knowledge of determinants of cancer development, progression and survival. Loss of apoptosis is a widely and deeply studied process and different approaches are being used to restore apoptosis in resistant cancer phenotype. Modulating the balance between pro-apoptotic and anti-apoptotic proteins is essential to induce apoptosis. It is becoming more understood that pharmacological inhibition of the proteasome might prove to be an effective option in improving TRAIL induced apoptosis in cancer cells. Keeping in view rapidly accumulating evidence of carcinogenesis, metastasis, resistance against wide ranging therapeutics and loss of apoptosis, better knowledge regarding tumor suppressors, oncogenes, pro-apoptotic and anti-apotptic proteins will be helpful in translating the findings from benchtop to bedside.
Department of Chemistry, GCU Lahore, Lahore, Pakistan E-mail : ammadahmad638@yahoo.com.
Muhammad Zahid
MZ
Qureshi
Mirna Azalea
MA
Romero
Rukset
R
Attar
Zeeshan
Z
Javed
Ammad Ahmad
AA
Farooqi
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D051017:Apoptosis Regulatory Proteins / Q000378:metabolism*; D000069286:Bortezomib / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D046988:Proteasome Endopeptidase Complex / Q000737:chemistry* / Q000378:metabolism; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism*
D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; D053221:TNF-Related Apoptosis-Inducing Ligand; D000069286:Bortezomib; D046988:Proteasome Endopeptidase Complex